Results.—Serum IgG in the HC sera pool recognized 85 protein spots and serum IgG from patients with AAV recognized $134 \pm 65$ different protein spots. We focused on protein recognized by at least 3/4 pools of patients with GPA and 2/3 pools of patients with MPA and CSS and not by HC and identified 20, seven and eight proteins, respectively. In addition, among the 330 spots recognized by at least one pool of patients with AAV, ten different spots were recognized by at least 6/10 pools. Among identified proteins, IgG reactivity was detected against alpha-enolase, lamin A/C and protein disulphide-isomerase A3. Interestingly, Ingenuity Pathway Analysis revealed that most of these antigens interact with TGF-β and signalling pathways such as Jun and MAPK.

Conclusion.— AECa detected in patients with AAV recognize cellular targets playing key roles in cell biology. Target antigens interact with protein and complexes known to play a crucial role in AAV pathophysiology.

http://dx.doi.org/10.1016/j.lpm.2013.02.005

A5

Orthotopic heart transplantation in eosinophilic granulomatosis with polyangiitis


1. Department of Internal Medicine, Paris, France
2. Department of cardiology and heart Transplantation, Milan, Italy
3. Department of Rheumatologic and Immunologic Disease, Cleveland, USA
4. Department of Cardiology, Angiology, and Respiratory Medicine, Heidelberg, Germany
5. Department of cardiovascular surgery, Buenos Aires, Argentina
6. Department of Cardiovascular and thoracic surgery, Paris, France
7. Department of Internal Medicine III (Cardiology and Angiology), Kiel, Germany
8. Department of cardiothoracic surgery, Pavia, Italy
9. Department of Rheumatology, Internal Medicine and Emergency Medicine, Milan, Italy
10. Division of Nephrology, Brescia, Italy
11. Department of cardiology and heart Transplantation, Brescia, Italy
12. Department of Rheumatology, Autoimmune and Metabolic Bone Diseases, Buenos Aires, Argentina

Introduction.— Heart involvement is the leading cause of death in eosinophilic granulomatosis with polyangiitis (EGPA) [1]. Transplant outcome after orthotopic heart transplantation (OHT) due to EGPA-related cardiomyopathy has been reported in a single patient [2].

Patients.— We conducted an international retrospective study of patients who went through OHT for EGPA-related cardiomyopathy between October 2000 and December 2009. A complete PubMed review was also performed.

Results.— Nine patients were identified. All had negative ANCA serology –

 EGPA and EGPA-related cardiomyopathy diagnoses were synchronous in five patients and in the other four patients were separated by 12 to 21 months.

Six patients’ explanted hearts (67%) showed histologic evidence of EGPA. Four patients (44%) died of sudden death after OHT, with survival time ranging from three to 60 months. Follow-up for the five surviving patients (56%) is 55 to 102 months.

EGPA relapse after OHT occurred in six patients (67%), within a period of two to 48 months.

Discussion.— This is the largest case series of patients who have gone through OHT for EGPA-related cardiomyopathy. It is essential to identify cardiac involvement early during the course of EGPA, for prompt treatment with corticosteroids and cyclophosphamide may allow recovery of the cardiac function [3,4]. In refractory patients, OHT can be performed with respect to the International Society of Heart and Lung Transplantation (ISHLT) guidelines [5], but it is of poor-prognosis. After OHT, recent data suggests that tacrolimus (TAC) and mycophenolate